Johanna Rossell

Senior Vice President, General Manager, Rare Disease at Sumitomo Pharma America

Speaker

Johanna has a broad and deep background across consumer goods and healthcare in the U.S. and global geographies. She has led multi-functional teams delivering strong results for companies including Procter & Gamble, Novartis, Merck, Biogen, and Sumitomo Pharma. She has demonstrated success leading new products to market in the U.S. and created integrated pre- and post-launch commercial plans, both in the U.S. and globally, including a Regenerative Medicine Advanced Therapy (RMAT) tissue-based product and several rare disease therapies. Her recent venture as Chief Commercial Officer of the biotech Enzyvant Therapeutics, she led the expansion of one of the few FDA-approved RMAT products, RETHYMIC. In her current role, she serves as SVP and GM, Rare Disease at Sumitomo Pharma America, Inc. Her wealth of knowledge paves the commercial vision for other tissue-based products to help patients living with rare diseases.